One-pot multi-enzyme (OPME) chemoenzymatic synthesis of sialyl-Tn-MUC1 and sialyl-T-MUC1 glycopeptides containing natural or non-natural sialic acid.

A series of STn-MUC1 and ST-MUC1 glycopeptides containing naturally occurring and non-natural sialic acids have been chemoenzymatically synthesized from Tn-MUC1 glycopeptide using one-pot multienzyme (OPME) approaches. In situ generation of the sialyltransferase donor cytidine 5'-monophosphate-sialic acid (CMP-Sia) using a CMP-sialic acid synthetase in the presence of an extra amount of cytidine 5'-triphosphate (CTP) and removal of CMP from the reaction mixture by flash C18 cartridge purification allow the complete consumption of Tn-MUC1 glycopeptide for quantitative synthesis of STn-MUC1. A Campylobacter jejuni β1-3GalT (CjCgtBΔ30-His6) mutant has been found to catalyze the transfer of one or more galactose residues to Tn-MUC1 for the synthesis of T-MUC1 and galactosylated T-MUC1. Sialylation of T-MUC1 using Pasteurella multocida α2-3-sialyltransferase 3 (PmST3) with Neisseria meningitidis CMP-sialic acid synthetase (NmCSS) and Escherichia coli sialic acid aldolase in one pot produced ST-MUC1 efficiently. These glycopeptides are potential cancer vaccine candidates.

[1]  N. Peat,et al.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.

[2]  Jianjun Li,et al.  Variants of the beta 1,3-galactosyltransferase CgtB from the bacterium Campylobacter jejuni have distinct acceptor specificities. , 2007, Glycobiology.

[3]  E. Schmitt,et al.  Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response. , 2008, Angewandte Chemie.

[4]  Huilei Yu,et al.  Chemoenzymatic synthesis of CMP-sialic acid derivatives by a one-pot two-enzyme system: comparison of substrate flexibility of three microbial CMP-sialic acid synthetases. , 2004, Bioorganic & medicinal chemistry.

[5]  Yanhong Li,et al.  Pasteurella multocida sialic acid aldolase: a promising biocatalyst , 2008, Applied Microbiology and Biotechnology.

[6]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[7]  Y. Malykh,et al.  N-Glycolylneuraminic acid in human tumours. , 2001, Biochimie.

[8]  Harshal A. Chokhawala,et al.  Highly efficient chemoenzymatic synthesis of naturally occurring and non-natural alpha-2,6-linked sialosides: a P. damsela alpha-2,6-sialyltransferase with extremely flexible donor-substrate specificity. , 2006, Angewandte Chemie.

[9]  Peng George Wang,et al.  Highly efficient chemoenzymatic synthesis of β1-3-linked galactosides. , 2010, Chemical communications.

[10]  Yanhong Li,et al.  PmST3 from Pasteurella multocida encoded by Pm1174 gene is a monofunctional α2–3-sialyltransferase , 2011, Applied Microbiology and Biotechnology.

[11]  S. Withers,et al.  Fluorescence activated cell sorting as a general ultra-high-throughput screening method for directed evolution of glycosyltransferases. , 2010, Journal of the American Chemical Society.

[12]  S. Sad,et al.  Biochemical Engineering of Surface α2–8 Polysialic Acid for Immunotargeting Tumor Cells* , 2000, The Journal of Biological Chemistry.

[13]  Yanhong Li,et al.  Decreasing the sialidase activity of multifunctional Pasteurella multocida α2-3-sialyltransferase 1 (PmST1) by site-directed mutagenesis. , 2011, Molecular bioSystems.

[14]  Qian Wan,et al.  From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine. , 2009, Journal of the American Chemical Society.

[15]  J. Taylor‐Papadimitriou,et al.  Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. , 2007, Glycobiology.

[16]  Li Ding,et al.  Efficient one-pot multienzyme synthesis of UDP-sugars using a promiscuous UDP-sugar pyrophosphorylase from Bifidobacterium longum (BLUSP). , 2012, Chemical communications.

[17]  H. Kunz,et al.  Synthesis of tumor-associated glycopeptide antigens. , 2002, Bioorganic & medicinal chemistry.

[18]  I. Brockhausen,et al.  Mucin‐type O‐glycans in human colon and breast cancer: glycodynamics and functions , 2006, EMBO reports.

[19]  J. Forstner.  Intestinal mucins in health and disease. , 1978, Digestion.

[20]  G. Springer.  T and Tn, general carcinoma autoantigens. , 1984, Science.

[21]  Shilpa A. Patil,et al.  Characterization of cancer associated mucin type O-glycans using the exchange sialylation properties of mammalian sialyltransferase ST3Gal-II. , 2012, Journal of proteome research.

[22]  C. Harding,et al.  Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines. , 2005, Journal of medicinal chemistry.

[23]  A. Varki,et al.  N-Glycolylneuraminic Acid Deficiency in Mice: Implications for Human Biology and Evolution , 2007, Molecular and Cellular Biology.

[24]  Zhongwu Guo,et al.  Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines. , 2006, Bioconjugate chemistry.

[25]  R. Dwek,et al.  The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. , 2008, Glycobiology.

[26]  Hai Yu,et al.  A multifunctional Pasteurella multocida sialyltransferase: a powerful tool for the synthesis of sialoside libraries. , 2005, Journal of the American Chemical Society.

[27]  A. Fisher,et al.  A sialyltransferase mutant with decreased donor hydrolysis and reduced sialidase activities for directly sialylating LewisX. , 2012, ACS chemical biology.

[28]  Ravibhushan Singh,et al.  MUC1: A target molecule for cancer therapy , 2007, Cancer biology & therapy.

[29]  Kam Y. Lau,et al.  PmST2: a novel Pasteurella multocida glycolipid α2-3-sialyltransferase. , 2011, Glycobiology.

[30]  A. Varki,et al.  Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. , 2009, Blood.

[31]  Yanhong Li,et al.  Efficient chemoenzymatic synthesis of sialyl Tn-antigens and derivatives. , 2011, Chemical Communications.

[32]  Jing-Wen Ma,et al.  A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy. , 2012, Journal of the American Chemical Society.

[33]  J. Taylor‐Papadimitriou,et al.  Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy. , 1994, Trends in biotechnology.

[34]  Zhongwu Guo,et al.  Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell. , 2007, Bioorganic & medicinal chemistry.

[35]  X. Chen,et al.  Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. , 2011, Cancer research.

[36]  M. Hollingsworth,et al.  Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. , 2006, Glycobiology.

[37]  A. Varki.  Uniquely human evolution of sialic acid genetics and biology , 2010, Proceedings of the National Academy of Sciences.

[38]  A. Varki,et al.  Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Chun-Hung Lin,et al.  Synthesis of Sialyl TN Glycopeptides – Enzymatic Sialylation by α2,6‐Sialyltransferase from Photobacterium damsela , 2005 .

[40]  A. Varki,et al.  Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. , 2008, Glycobiology.